开云app官网登录入口网页版-官方正版

#Filgotinib#

9篇内容 | 1119人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2118382, encodeId=717621183824e, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>治疗<a href='/topic/show?id=05c46645ec3' target=_blank style='color:#2F92EE;'>#溃疡性结肠炎#</a>可以快速诱导症状缓解，Filgotinib是一种每日一次的口服Janus激酶1的抑制剂，用于治疗多种炎症性疾病，即<a href='/topic/show?id=efe510226b0' target=_blank style='color:#2F92EE;'>#JAK1抑制剂#</a>, objectTitle=AJG：Filgotinib治疗溃疡性结肠炎可以快速诱导症状缓解, objectType=article, longId=748931, objectId=7947e4893162, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016434455_4754896.png, objectUrl=/article/show_article.do?id=7947e4893162, replyNumber=0, likeNumber=77, createdTime=2023-03-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7947e4893162, moduleTitle=AJG：Filgotinib治疗溃疡性结肠炎可以快速诱导症状缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7947e4893162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469356, encodeId=2e61146935652, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=Lancet：JAK1抑制剂Filgotinib治疗中重度溃疡性结肠炎, objectType=article, longId=212293, objectId=607e2122932e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607e2122932e, replyNumber=0, likeNumber=50, createdTime=2021-06-06, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607e2122932e, moduleTitle=Lancet：JAK1抑制剂Filgotinib治疗中重度溃疡性结肠炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=607e2122932e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469355, encodeId=21a31469355fb, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=Jyseleca（filgotinib）治疗类风湿性关节炎：已获得日本和欧盟的批准, objectType=article, longId=201256, objectId=8539201256b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8539201256b5, replyNumber=0, likeNumber=68, createdTime=2020-09-28, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8539201256b5, moduleTitle=Jyseleca（filgotinib）治疗类风湿性关节炎：已获得日本和欧盟的批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8539201256b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469354, encodeId=759a1469354c1, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, objectType=article, longId=195471, objectId=2fd71954e152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fd71954e152, replyNumber=0, likeNumber=68, createdTime=2020-06-09, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fd71954e152, moduleTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2fd71954e152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469353, encodeId=2c2a1469353a0, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, objectType=article, longId=194505, objectId=e08f19450510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08f19450510, replyNumber=0, likeNumber=60, createdTime=2020-05-23, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08f19450510, moduleTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e08f19450510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469352, encodeId=82931469352f3, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=吉利德与卫材达成协议：在日本共同推广非洛替尼（Filgotinib）治疗类风湿性关节炎, objectType=article, longId=185338, objectId=b9ff1853386c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9ff1853386c, replyNumber=0, likeNumber=68, createdTime=2019-12-29, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9ff1853386c, moduleTitle=吉利德与卫材达成协议：在日本共同推广非洛替尼（Filgotinib）治疗类风湿性关节炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b9ff1853386c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469351, encodeId=fb54146935158, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, objectType=article, longId=184287, objectId=1a1218428e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1218428e0d, replyNumber=0, likeNumber=70, createdTime=2019-12-08, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1218428e0d, moduleTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1a1218428e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469350, encodeId=60041469350ac, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=JAMA：Filgotinib治疗难治性活动性类风湿关节炎, objectType=article, longId=176135, objectId=33ad1e61350f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33ad1e61350f, replyNumber=0, likeNumber=76, createdTime=2019-07-26, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33ad1e61350f, moduleTitle=JAMA：Filgotinib治疗难治性活动性类风湿关节炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=33ad1e61350f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469349, encodeId=14fd146934978, content=<a href='/topic/show?id=d5ede4469b' target=_blank style='color:#2F92EE;'>#Filgotinib#</a>, objectTitle=Lancet：好消息！Filgotinib可使中重度Crohn病患者临床缓解, objectType=article, longId=84402, objectId=004784402db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=004784402db, replyNumber=0, likeNumber=100, createdTime=2016-12-16, rootId=0, userName=xirongguo, userId=91457016663, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=004784402db, moduleTitle=Lancet：好消息！Filgotinib可使中重度Crohn病患者临床缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=004784402db)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Filgotinib

2020-05-29

showtest (审核中...)

前往app查看评论内容

#Filgotinib#治疗#溃疡性结肠炎#可以快速诱导症状缓解，Filgotinib是一种每日一次的口服Janus激酶1的抑制剂，用于治疗多种炎症性疾病，即#JAK1抑制剂#

AJG：Filgotinib治疗溃疡性结肠炎可以快速诱导症状缓解

2023-03-09发表于上海

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

Lancet：JAK1抑制剂Filgotinib治疗中重度溃疡性结肠炎

2021-06-06

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

Jyseleca（filgotinib）治疗类风湿性关节炎：已获得日本和欧盟的批准

2020-09-28

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效

2020-06-09

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点

2020-05-23

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

吉利德与卫材达成协议：在日本共同推广非洛替尼（Filgotinib）治疗类风湿性关节炎

2019-12-29

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

2019-12-08

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

JAMA：Filgotinib治疗难治性活动性类风湿关节炎

2019-07-26

xirongguo (审核中...)

前往app查看评论内容

#Filgotinib#

Lancet：好消息！Filgotinib可使中重度Crohn病患者临床缓解

2016-12-16

科室
- - 订阅+
  - 更多科室
工具
服务